About Dr Kanak Kanti De

Owner of this website. Have written on SeekingAlpha, Forbes, Motley Fool etcetera.

Premarket Biotech Digest – $AVGR announces positive data, $CXRX to be investigated, $CYTX receives BARDA nod,

Microbot Medical Inc. ($MBOT) announced receiving a new patent from the Canadian Intellectual Property Office. The new patent covers the company’s Self-Cleaning Shunt, specifically an inlet head for use on shunts. Microbot has an  exclusive license to the patent from the Technion - Israel [...]

By |June 1st, 2017|Digest|0 Comments

Four Investment Ideas for January 2017 – $MDCO, $CDTX, $AQXP, $ARQL

This month's investment idea article discusses four stocks - The Medicines Company, Cidara Therapeutics, Aquinox and ArQule. Of these, $MDCO is a top idea with multiple revenue-earning products and 2 major pipeline product candidates with upcoming data. $ARQL is another important idea, also with upcoming catalysts. The other two are [...]

By |January 29th, 2017|Monthly Investment Ideas|4 Comments

Swing Trading Room – The Details Are Here

How to Subscribe: First, go here - http://drkkd.com/whats-on-offer/ - and select the swing trading option on the top right hand corner. Trial is for 2 months, $40; thereafter, if you wish to continue, it is $1199/yearly. If you subscribe now, but wish to cancel before the annual payment kicks in [...]

By |January 27th, 2017|News|0 Comments

A quick look at Recro Pharma $REPH

Recro Pharma develops non-opioid drugs for pain management. REPH is targeting an NDA this year for its fast-acting IV version of Meloxicam, a well-known NSAID whose oral version just takes too long to work, but has been shown to be effective. REPH is even developing an intramuscular delivery format for [...]

By |January 22nd, 2017|Opinions|0 Comments

My Top Picks for 2017…and beyond – $RHHBY $HALO $BLCM

I had three picks for 2016, Relypsa $RLYP, Acadia $ACAD and Progenics $PGNX. $RLYP was acquired at a 60% premium by a large Swiss company. ACAD got its drug approved, and just hit another successful trial for pimavanserin. PGNX has done very well. Oral Relistor got approved, and it has [...]

By |December 29th, 2016|Monthly Investment Ideas|2 Comments

Conviction Buy List November – $BLCM $HALO $AKBA

I removed Gilead $GILD from the list because I see no short term hope for this stock unless there's some acquisition. Even good trial results aren't helping. This doesn't mean the stock needs to be sold; it just means there are better buys out there. I removed Dynavax $DVAX because [...]

By |December 4th, 2016|Monthly Investment Ideas|0 Comments

Is Actelion an attractive buy for Johnson & Johnson? $JNJ $ALIOPY

Johnson & Johnson $JNJ is reported to be negotiating the acquisition of Swiss pharma company Actelion $ALIOPY. While the company has confirmed that it is engaged in preliminary discussions, it refused to divulge any further information. It is also one of the most prominent biotech companies in Europe. In the [...]

By |November 28th, 2016|Opinions|0 Comments

Three Investment Ideas – November 2016

Halozyme The top three investment angles for Halozyme are that, one, it is a small company with an approved product, two, its Enhanze platform is partnered with a number of large biotech and generates royalties, and three, it has a late stage pipeline with strong potential. Halozyme (HALO) is a [...]

By |November 26th, 2016|Monthly Investment Ideas|0 Comments

Premarket Biotech Digest: $VRX Related Fraud, $AZN $AGN $1.5bn Licensing Deal, $CYCC Positive Data

Valeant's liaison with Philidor paid millions to promote Philidor interest, including acquisition option Valeant (VRX) is entangled in a legal tangle. Details are emerging that former VRX and Philidor liason Gary Tanner was paid up to $10mn by Philidor through CEO Andrew Davenport to [...]

By |November 18th, 2016|Digest|0 Comments

Premarket Biotech Digest: $AMGN Positive, $GILD Mixed Results, $SRNE Acquires

Amgen's erenumab shows positive results in second late-stage migraine study - $AMGN phase 3 STRIVE study has shown positive results in migraine patients, meeting primary endpoint of statistically valid change from baseline in mean monthly migraine days at week 24 compared to placebo.It was [...]

By |November 17th, 2016|Digest|0 Comments

Premarket Biotech Digest: $ACAD New Trial, $ITEK Catalyst, $JAZZ Insider Buy

According to my biotech stock screener, Inotek $ITEK is trading near its 52-week low, has total cash of $137 million and a market cap of only $185 million (these figures could be wrong, please fact check), and has an upcoming catalyst, results for Trabodenoson [...]

By |November 16th, 2016|Digest|0 Comments

Premarket Biotech Digest: $GALT Announces Positive Results, $PFE Considers Sale of Consumer Health Business, $ANTH Fails in Lupus Study

Focus Ticker: Galectin Therapeutics Galectin Therapeutics $GALT announced on Thursday that it observed positive results from its Phase 2a clinical trial, evaluating lead product candidate GR-MD-02 for the treatment of moderate-to-severe plaque psoriasis. All five subjects, who took the treatment with 8 mg/kg of GR-MD-02 administered every other week showed [...]

By |November 11th, 2016|Digest|0 Comments

Biotech Trade Alerts Archive -2016-11-10- $DMTX, $BMY, $ANTH, $TENX, $AZN, $PFE

DRKKD.com Real Time Biotech Trade Alert Service November 10, 2016. Tickers covered: DMTX, BMY, ANTH, TENX, AZN, PFE *** L3 or above subscription required to read further... Login or Subscribe/Upgrade here Posted: Thu, 10 Nov 2016 09:53:06 -0500 Ticker: DMTX InPortfolio: No ConvictionBuy: No Price: 4.50 RiskProfile: High [...]

By |November 11th, 2016|Real Time Trade Alerts|0 Comments

$DMTX reports Q3 results

Dimension Therapeutics $DMTX reported Q3 EPS of -$0.58, missing the guidance by $0.03. Revenue was $2.76 million, a growth of 34%, Y-o-Y, and beating the estimate by $0.6 million.

By |November 10th, 2016|News|0 Comments

$BMY signs global licensing agreement with Nitto Denko

Bristol-Myers Squibb $BMY signed a global licensing agreement with Japanese firm Nitto Denko $NDEKF for the development and commercialization of Nitto�s siRNA molecules targeting heat shock protein 47 (HSP47) formulations containing vitamin A. The agreement includes Nitto�s lead product candidate, Phase 1b-stage ND-L02-s0201, for the treatment of advanced liver fibrosis [...]

By |November 10th, 2016|News|0 Comments


Anthera Pharmaceuticals� $ANTH fell sharply amid heavy trading volume in response to its announcement that CHABLIS-SC1, evaluating blisibimod for the treatment of patients with active systemic lupus erythematosus (SLE) failed to achieve its primary endpoint.

By |November 10th, 2016|News|0 Comments

$TENX reports Q3 results

Tenax Therapeutics $TENX posted Q3 EPS of -$0.15, beating the guidance by $0.02.

By |November 10th, 2016|News|0 Comments

$AZN reports Q3 results

AstraZeneca $AZN reported Q3 EPS of $1.32, beating the guidance by $0.58. Revenue was $5.7 billion, a drop of 4.2$, Y-o-Y, and missing the estimate by $250 million.

By |November 10th, 2016|News|0 Comments

$PFE considering sale or spin-off of consumer health unit

Pfizer $PFE is considering a potential sale or spinoff of its consumer health unit that could value the business as much as $14 billion, according to Reuters� report. Divesting this division, which includes Advil and Chapstick, would be one the company biggest ever corporate moves since cancelling a $160 billion [...]

By |November 10th, 2016|News|0 Comments

Premarket Biotech Digest: $RGRX Commences ARISE-2, $ALXN Defers 10Q Filing, $NVAX Cuts Workforce

[/toggle] Enrollment has started in RegeneRx Biopharmaceuticals’ $RGRX 500-participants Phase 3 clinical trial, ARISE-2, evaluating lead product candidate RGN-259 (Thymosin beta 4) for the treatment of patients with dry eye syndrome, neurotrophic Keratopathy and other corneal disorders. The primary endpoints are the alteration in ocular [...]

By |November 10th, 2016|Digest|0 Comments